

Results of Renounceable Rights Offer

Transformative, concussion management technology company, **HITIQ Limited** (ASX: **HIQ**) (**HITIQ** or the **Company**) refers to its Renounceable Rights Offer ("Rights Issue Offer") as announced to the ASX on 1 November 2022, and provides the following summary of subscriptions and Shortfall as at the close of the Rights Issue Offer on Friday 9 December 2022.

	No# of Shares	\$
Number of Rights under the Rights Issue Offer	211,870,429	6,356,113
Number of Rights and Top Up Shares taken up by	89,160,273	2,674,808
Eligible Shareholders		
Shortfall of Entitlement Issue	122,710,156	3,681,305

The Company also advises that it has received formal Shortfall Subscriptions for 42,899,998 Shortfall Shares representing \$1,287,000 at the time of this announcement.

The Company wishes to further advise that it has received significant interest for the remaining shortfall and should these additional subscriptions proceed, they will be communicated to shareholders if and when formalised and received. Note, the Company may elect to batch these addition subscriptions. Irrespective, the Directors and company's advisers will endeavour to secure additional investors for the remaining Shortfall within the 3-month timeframe post Rights Issue Offer close.

Given the minimum subscription has been received, the Company expects to issue and allot the Shares and Options under the Rights Issue Offer by 16 December 2022 in accordance with the previously advised timetable.

- ENDS -

Authorised for release by the Board of HITIQ Limited.

For more information, contact:

Mike Vegar
CEO & MD
HITIQ Limited
investors@hitiq.com

Elvis Jurcevic Investor Relations +61 408 268 271 ei@hitig.com

HITIQ Limited ACN 609 543 213 ASX: HIQ

HITIQ.COM

Corporate Office

Level 2, 9-17 Raglan Street South Melbourne VIC 3205

E: investors@hitiq.com

Directors

Otto Buttula Michael Vegar Phillip Carulli Glenn Smith Aidan Clarke

Non-Executive Chair Managing Director Non-Executive Director Non-Executive Director Non-Executive Director

About HITIQ

HITIQ Limited (ASX: **HIQ**) operates in the healthcare equipment sector, providing and further developing a transformative, end-to-end concussion management technology platform. This platform aims to provide a total concussion ecosystem whereby the Company's products support the identification, monitoring and management of sport related brain injury. HITIQ's product suite utilises high-end technology that will span multiple domains – from early detection and surveillance to assessment and rehabilitation technology tools.

HITIQ is targeting a growing worldwide concussion management market including elite and recreational sport, clinical practitioners, military, research, and combat sports. The Company's first commercial partner is the Australian Football League, with current strategy initiatives expanding commercially into Rugby League, Rugby Union, Ice Hockey, Lacrosse, MMA and American Football (particularly the NCAA). The market opportunity globally represents ~500k athletes within the elite market and ~10million in the consumer market.